Arthrosi Therapeutics Secures $153M in Series E Funding for Gout Treatment Development

Arthrosi Therapeutics, a San Diego-based biotech company, has successfully raised $153 million in a Series E financing round to advance its gout treatment candidate, pozdeutinurad. This substantial investment positions the company to deliver data from two pivotal phase 3 trials in 2026, marking a significant milestone in the development of novel therapies for gout.

Funding Details and Investor Support

The Series E round was led by Prime Eight Capital, with participation from CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech, and existing shareholders. This latest funding comes two years after Arthrosi's $75 million Series D round, demonstrating continued investor confidence in the company's approach to gout treatment.

Clinical Trial Progress and Timeline

Arthrosi has already completed enrollment for two phase 3 gout trials earlier this year, with the second study's enrollment wrapping up in August. The company has outlined an ambitious timeline, anticipating two data releases in 2026. The first pivotal data on pozdeutinurad is expected to be reported in the second quarter of next year, setting the stage for a potential regulatory filing.

Pozdeutinurad: A New Approach to Gout Treatment

Pozdeutinurad is an inhibitor of URAT1, a transporter that has been a target for gout drugs since the approval of probenecid in 1951. Unlike earlier gout medications that affected multiple targets and caused various side effects, pozdeutinurad aims to be a more potent and specific URAT1 inhibitor. This approach builds on lessons learned from previous attempts in the field, including AstraZeneca's Zurampic, which was discontinued in 2018 despite initial promise.